Neurological disorder specialist
Uwe Meya is taking over as Chief Medical Officer at Barcelona-based orphan drug developer Minoryx Therapeutics. Meya will advance the clinical development of Minoryx lead candidate MIN-102 for adrenoleukodystrophy.
Meya, a neurologist and psychiatrist, joins Minoryx Therapeutics from Swiss Lupin Atlantis Holdings SA, where he was responsible for clinical strategy and implementation of studies with new clinical entities in various indications, including neurodegenerative disorders.
Previously, he worked at Synosia Therapeutics, Roche and Novartis. Meya received his medical degree as well as his doctorate in psychiatry from the University of Aachen (Germany). He is a member of the European College of Neuropsychopharmacology as well as the International Parkinson and Movement Disorder Society and is a founding member of the International College of Geriatric Psychoneuropharmacology.
pixabay.com - geralt
SK Bioscience
wikioedia.org - Von http://web2.airmail.net/uthman/specimens/index.html, Gemeinfrei, https://commons.wikimedia.org/w/index.php?curid=841015